You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 16, 2024

Claims for Patent: 6,727,286


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 6,727,286
Title: Pharmaceutical composition of 2-(4-isobutylphenyl) propionic acid
Abstract:The present invention provides a pharmaceutical composition comprising an aqueous solution of arginine and ibuprofen, wherein the molar ratio of arginine to ibuprofen is less than 1:1, as well as a method of making the same. The present invention also provides a method of treating a condition chosen from pain, inflammation, fever, and/or other conditions alleviated by ibuprofen comprising administering a pharmaceutical composition comprising an aqueous solution of arginine and ibuprofen, wherein the molar ratio of arginine to ibuprofen is less than 1:1.
Inventor(s): Pavliv; Leo (Morrisville, NC)
Assignee: Cumberland Pharmaceuticals Inc. (Nashville, TX)
Application Number:09/985,246
Patent Claims: 1. A pharmaceutical composition comprising an aqueous solution of arginine and ibuprofen, wherein the molar ratio of arginine to ibuprofen is less than or equal to 0.97:1.

2. The pharmaceutical composition of claim 1, wherein the aqueous solution of arginine and ibuprofen has been terminally sterilized.

3. The pharmaceutical composition of claim 1, wherein the aqueous solution of arginine and ibuprofen has been lyophilized.

4. The pharmaceutical composition of claim 1, wherein the ibuprofen is (RS)-Ibuprofen.

5. The pharmaceutical composition of claim 1, wherein the ibuprofen is (S)-Ibuprofen.

6. The pharmaceutical composition of claim 1, wherein the arginine is L-arginine.

7. The pharmaceutical composition of claim 1, wherein the arginine is D-arginine.

8. The pharmaceutical composition of claim 1, wherein the molar ratio of arginine to ibuprofen is from about 0.10:1 to about 0.97:1.

9. The pharmaceutical composition of claim 8, wherein the molar ratio of arginine to ibuprofen is 0.92:1.

10. The pharmaceutical composition of claim 8, wherein the molar ratio of arginine to ibuprofen is 0.60:1.

11. The pharmaceutical composition of claim 8, wherein the molar ratio of arginine to ibuprofen is 0.97:1.

12. A method of making a pharmaceutical composition comprising an aqueous solution of arginine and ibuprofen, the method comprising dissolving arginine in water to form an arginine solution and dissolving ibuprofen in the arginine solution to form the aqueous solution of arginine and ibuprofen, wherein the molar ratio of arginine to ibuprofen is less than or equal to 0.97:1.

13. The method of claim 12, wherein the molar ratio of arginine to ibuprofen is from about 0.10:1 to about 0.97:1.

14. The method of claim 12, wherein the molar ratio of arginine to ibuprofen is 0.92:1.

15. The method of claim 12, wherein the molar ratio of arginine to ibuprofen is 0.60:1.

16. The method of claim 12, wherein the molar ratio of arginine to ibuprofen is 0.97:1.

17. The method of claim 12, further comprising terminally sterilizing the aqueous solution of arginine and ibuprofen.

18. The method of claim 12, further comprising lyophilizing the aqueous solution of arginine and ibuprofen.

19. The method of claim 12, wherein the ibuprofen is (RS)-Ibuprofen.

20. The method of claim 12, wherein the ibuprofen is (S)-Ibuprofen.

21. The method of claim 12, wherein the arginine is L-arginine.

22. The method of claim 12, wherein the arginine is D-arginine.

23. A method of treating one or more conditions chosen from pain, inflammation, fevers, and, patent ductus arteriosis comprising administering to a patient in need thereof an effective amount of an aqueous solution of arginine and ibuprofen, wherein the molar ratio of arginine to ibuprofen is less than or equal to 0.97:1.

24. The method of claim 23, wherein the molar ratio of arginine to ibuprofen is from about 0.10:1 to about 0.97:1.

25. The method of claim 23, wherein the molar ratio of arginine to ibuprofen is 0.92:1.

26. The method of claim 23, wherein the molar ratio of arginine to ibuprofen is 0.60:1.

27. The method of claim 23, wherein the molar ratio of arginine to ibuprofen is 0.97:1.

28. The method of claim 23, wherein the administration occurs via intravenous injection.

29. The method of claim 23, wherein the administration occurs via intramuscular injection.

30. The method of claim 23, wherein the administration occurs orally.

31. The method of claim 23, wherein the effective amount is from about 100 mg to about 800 mg of ibuprofen.

32. The method of claim 31, wherein the effective amount is about 400 mg of ibuprofen.

33. The method of claim 23, wherein the effective amount is about 7.5 mg/kg of ibuprofen.

34. The method of claim 23, wherein the condition is pain.

35. The method of claim 23, wherein the condition is inflammation.

36. The method of claim 23, wherein the condition is fever.

37. A pharmaceutical composition comprising an aqueous solution of arginine and ibuprofen prepared according to the method of claim 12.

38. The method of claim 23, wherein the condition is patent ductus arteriosis.

39. The pharmaceutical composition of claim 1, the molar ratio of arginine to ibuprofen is from about 0.60:1 to about 0.97:1.

40. The pharmaceutical composition of claim 39, wherein said molar ratio is from about 0.92:1 to about 0.97:1.

41. The method of claim 12, wherein the molar ratio of arginine to ibuprofen is from about 0.60:1 to about 0.97:1.

42. The method of claim 41, wherein the molar ratio of arginine to ibuprofen is from about 0.92:1 to about 0.97:1.

43. The method of claim 23, wherein the molar ratio of arginine to ibuprofen is from about 0.60:1 to about 0.97:1.

44. The method of claim 43, wherein the molar ratio of arginine to ibuprofen is from about 0.92:1 to about 0.97:1.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.